Because a particularly pathogenic set of AD-relevant pro-inflammatory miRNAs appear to be under NF-kB-mediated transcriptional control it seems reasonable to speculate that in addition to AM strategies, NF-kB inhibitors may play some future role in novel therapeutic strategies to address neurodegenerative diseases in general and to AD in particular (Lukiw et al., 2008; Cui et al., 2010; Lukiw, 2012a,b, 2013a; Devier et al., 2015; Kaur et al., 2015; Srinivasan and Lahiri, 2015). This evidence concerns the gene NFKB1 and neurodegenerative disease.